Design Therapeutics is a biopharmaceutical company pioneering small-molecule genomic medicines for serious genetic diseases with significant unmet medical need. The company’s approach combines its understanding of gene regulation with the established capabilities of small molecules to develop therapies aimed at the underlying causes of genetic disorders. Its GeneTAC (Gene Targeted Chimera) platform is designed to support this work by targeting disease-related gene activity.

Design Therapeutics is advancing a pipeline focused initially on monogenic repeat expansion disorders. Its programs include candidates for Friedreich ataxia, Fuchs endothelial corneal dystrophy, myotonic dystrophy, and Huntington’s disease. The company describes its therapeutic candidates as being developed with the goal of bringing functional cures to these conditions; the information provided does not indicate that any are approved or commercially available.

Based in Carlsbad, California, Design Therapeutics also provides information for patients about expanded access programs and shares corporate, financial, and clinical development updates with investors and the public. Its work centers on translating genomic insights into small-molecule treatment approaches for inherited diseases.